Cargando…

Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis

SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Rungjirajittranon, Tarinee, Siriwannangkul, Theerapat, Kungwankiattichai, Smith, Leelakanok, Nattawut, Rotchanapanya, Wannaphorn, Vittayawacharin, Pongthep, Mekrakseree, Benjamaporn, Kulchutisin, Kamolchanok, Owattanapanich, Weerapat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659296/
https://www.ncbi.nlm.nih.gov/pubmed/36358658
http://dx.doi.org/10.3390/cancers14215239
_version_ 1784830166332080128
author Rungjirajittranon, Tarinee
Siriwannangkul, Theerapat
Kungwankiattichai, Smith
Leelakanok, Nattawut
Rotchanapanya, Wannaphorn
Vittayawacharin, Pongthep
Mekrakseree, Benjamaporn
Kulchutisin, Kamolchanok
Owattanapanich, Weerapat
author_facet Rungjirajittranon, Tarinee
Siriwannangkul, Theerapat
Kungwankiattichai, Smith
Leelakanok, Nattawut
Rotchanapanya, Wannaphorn
Vittayawacharin, Pongthep
Mekrakseree, Benjamaporn
Kulchutisin, Kamolchanok
Owattanapanich, Weerapat
author_sort Rungjirajittranon, Tarinee
collection PubMed
description SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcomes. Intriguingly, the overall survival (OS) and relapse-free survival (RFS) outcomes were similar in patients who had de novo AML with intermediate-risk cytogenetics with and without RUNX1(mut). Our study endorsed an unfavorable prognosis of this entity. ABSTRACT: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1(wt)). To assess the clinical outcomes of AML with and without RUNX1(mut), we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1(mut); 108 with RUNX1(w)(t)). There were no significant differences in the median OS and RFS of the RUNX1(mut) and RUNX1(wt) groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the RUNX1(mut) group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the RUNX1(wt) group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and RUNX1(mut) had poor prognoses. Nonetheless, in de novo AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable.
format Online
Article
Text
id pubmed-9659296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96592962022-11-15 Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis Rungjirajittranon, Tarinee Siriwannangkul, Theerapat Kungwankiattichai, Smith Leelakanok, Nattawut Rotchanapanya, Wannaphorn Vittayawacharin, Pongthep Mekrakseree, Benjamaporn Kulchutisin, Kamolchanok Owattanapanich, Weerapat Cancers (Basel) Article SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcomes. Intriguingly, the overall survival (OS) and relapse-free survival (RFS) outcomes were similar in patients who had de novo AML with intermediate-risk cytogenetics with and without RUNX1(mut). Our study endorsed an unfavorable prognosis of this entity. ABSTRACT: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1(wt)). To assess the clinical outcomes of AML with and without RUNX1(mut), we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1(mut); 108 with RUNX1(w)(t)). There were no significant differences in the median OS and RFS of the RUNX1(mut) and RUNX1(wt) groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the RUNX1(mut) group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the RUNX1(wt) group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and RUNX1(mut) had poor prognoses. Nonetheless, in de novo AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable. MDPI 2022-10-26 /pmc/articles/PMC9659296/ /pubmed/36358658 http://dx.doi.org/10.3390/cancers14215239 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rungjirajittranon, Tarinee
Siriwannangkul, Theerapat
Kungwankiattichai, Smith
Leelakanok, Nattawut
Rotchanapanya, Wannaphorn
Vittayawacharin, Pongthep
Mekrakseree, Benjamaporn
Kulchutisin, Kamolchanok
Owattanapanich, Weerapat
Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title_full Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title_fullStr Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title_full_unstemmed Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title_short Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
title_sort clinical outcomes of acute myeloid leukemia patients harboring the runx1 mutation: is it still an unfavorable prognosis? a cohort study and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659296/
https://www.ncbi.nlm.nih.gov/pubmed/36358658
http://dx.doi.org/10.3390/cancers14215239
work_keys_str_mv AT rungjirajittranontarinee clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT siriwannangkultheerapat clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT kungwankiattichaismith clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT leelakanoknattawut clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT rotchanapanyawannaphorn clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT vittayawacharinpongthep clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT mekraksereebenjamaporn clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT kulchutisinkamolchanok clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis
AT owattanapanichweerapat clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis